Costus root Dolomiaea costus (Falc.) Kasana & A.K.Pandey
Also called: Saussurea costus (synonym), Saussurea lappa (synonym), Aucklandia lappa (synonym), Aucklandia costus (synonym), muxiang (Aucklandiae Radix), qust
Costus is the dried root of a Himalayan daisy-family herb, long known as Saussurea costus or S. lappa, used in Chinese (muxiang) and Unani (qust) medicine. Wild plants are critically endangered and CITES Appendix I-listed; human trials are scarce.
- Category
- Botanical
- Part used
- Dried root (the popular medicinal material comes from cultivated plants)
- Strongest evidence
- C Limited
- Native range
- Native from northern Pakistan to China and northern Vietnam (POWO: "N. Pakistan to China and N. Vietnam")
- Reviewed
- 2026-10-29
Class 3 Limited studies in people. This entry cites 2 RCTs of costus alone: oral Qust (costus), 1.5 g twice daily with honey, versus another herb (Aristolochia rotunda) for menstrual pain, and topical costus oil versus placebo (route: topical) in postmenopausal women. [3]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CHormones and reproduction1 topic
DSeveral areas, whole body or blood1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Period pain (primary dysmenorrhea) | C | A single-blind randomized study compared costus root (1.5 g twice daily on cycle days 1-5 for three cycles) with another Unani herb, without placebo; pain scores fell in both groups, more with costus. [3] |
| Digestive, anti-inflammatory and antitumor activity | D | A 2026 review lists gastrointestinal, anti-inflammatory and antitumor pharmacological effects of costus and its constituents, and calls for refined methods, mechanistic studies and strengthened clinical trials. [2] |
Main constituents: Sesquiterpene lactones costunolide and dehydrocostus lactone, described as its core active metabolites [1]; 335 compounds reported, including sesquiterpenes, sesquiterpene dimers and flavonoids [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Root powder 1.5 g twice daily with 5 mL honey on days 1-5 of three menstrual cycles (comparative dysmenorrhea study). [3]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)1 found
Each names the exact material tested, which may differ from a supplement.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Substitution risk: kidney-toxic Aristolochia roots containing aristolochic acid (Qing-Muxiang, from Aristolochia debilis and A. contorta) have been used confusedly as substitutes for costus root (Muxiang). [4]
- Costunolide and dehydrocostus lactone are two of the three allergens in the sesquiterpene lactone mix used to patch-test for Compositae (daisy-family) contact allergy; about 1% of patients tested in Europe react. [6]
- A 2025 review notes that multiple studies indicate costus root extracts may cause adverse reactions. [1]
Identity, quality and standardization
- Several plants are sold under the trade name Muxiang, including Vladimiria and Inula species and Aristolochia debilis; ITS and 5S rRNA sequences differed from these substitutes and contain unique changes that may serve as markers. [5]
- GC-MS profiles of the essential oil, with hierarchical clustering, separated costus root from Vladimiria, Inula and Aristolochia roots. [4]
Regulatory status
- International trade: CITES Appendix I (listed under Saussurea costus; in effect since 1 August 1985, after earlier listing in Appendix II from 1975). [8]
- US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [9]
- US: No NDI notification naming costus (Saussurea costus or S. lappa, Dolomiaea costus) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [10]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Costunolide and dehydrocostus lactone Sesquiterpene lactones [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming costus (Saussurea costus or S. lappa, Dolomiaea costus) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of costus root (Saussurea costus) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
- IARC classifies aristolochic acid and plants containing it in Group 1 (Volumes 82, 100A); this applies to Aristolochia substitutes, not to costus itself. [P3]
- NTP technical reports list checked 2026-10-29: no report on costus found. [P4]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- Shum et al. (2007): owing to similar morphology and trade names, Vladimiria roots (Chuan-Muxiang), Inula roots (Tu-Muxiang) and aristolochic-acid-containing Aristolochia roots (Qing-Muxiang) are often used confusedly as substitutes; GC-MS essential-oil profiling distinguished them. [P5]
- Chen et al. (2008): Vladimiria, Inula and Aristolochia debilis are traded under the name Muxiang; ITS and 5S rRNA sequences differ from the substitutes and contain unique changes that may serve as differentiation markers. [P6]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test of the dietary ingredient (at least one appropriate test or examination before use) — 21 CFR 111.75(a)(1)(i) requires identity verification of every component that is a dietary ingredient, unless FDA exempts the firm on petition under 111.75(a)(1)(ii). [P7]
- Species authentication (GC-MS essential-oil profile or ITS/5S rRNA DNA sequencing) — Several roots, including Aristolochia, are traded as Muxiang (Chen et al. 2008). [P6]
- Aristolochic acid screen — Aristolochic-acid-containing Aristolochia roots (Qing-Muxiang) have been used as substitutes (Shum et al. 2007). [P5]
Supply and conservation
- IUCN Red List: Critically Endangered (CR) (assessed under the name Saussurea costus), via GBIF species API, retrieved 2026-10-29. [P8]
- CITES Appendix I (listed under Saussurea costus; in effect since 1 August 1985, after earlier listing in Appendix II from 1975). [P9]
- Wild Saussurea lappa is highly endangered, while the dried root of cultivated plants is the common medicinal material (Chen et al. 2008). [P6]
- Aucklandia lappa is extensively cultivated in China (Chen et al. 2025). [P1]
- India lists Saussurea costus among 13 medicinal plants receiving a 75% cultivation-cost subsidy. [P10]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Chen J, et al. Aucklandia lappa Decne.: a review of its botany, cultivation, ethnopharmacology, phytochemistry, pharmacology, and practical applications. Front Pharmacol 2025;16:1659831 (PMID 41158126), 2025-10-13. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. Agents classified by the IARC Monographs (list of classifications, checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (list checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- Shum KC, et al. Authentication of Radix Aucklandiae and its substitutes by GC-MS and hierarchical clustering analysis. J Sep Sci 2007;30(18):3233-9 (PMID 18004716), 2007-12. pubmed.ncbi.nlm.nih.gov
- Chen F, et al. Authentication of Saussurea lappa, an endangered medicinal material, by ITS DNA and 5S rRNA sequencing. Planta Med 2008;74(8):889-92 (PMID 18537077), 2008-06. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75 (current as of October 27, 2026), 2026-10-27. ecfr.gov
- GBIF species API: IUCN Red List category for Saussurea costus, 2026-10-29. api.gbif.org
- UNEP-WCMC / CITES Secretariat. Species+: Saussurea costus (synonyms Saussurea lappa, Dolomiaea costus), CITES listing (retrieved 2026-10-29), 2026-10-29. speciesplus.net
- Anmol, et al. Ethnopharmacologically important highly subsidized Indian medicinal plants: systematic review on their traditional uses, phytochemistry, pharmacology, quality control, conservation status and future prospective. J Ethnopharmacol 2024;320:117385 (PMID 37951375), 2024-02-10. pubmed.ncbi.nlm.nih.gov
Sources
- Chen J, et al. Aucklandia lappa Decne.: a review of its botany, cultivation, ethnopharmacology, phytochemistry, pharmacology, and practical applications. Front Pharmacol 2025;16:1659831 (PMID 41158126), 2025-10-13. pubmed.ncbi.nlm.nih.gov
- Wu G, et al. Traditional uses, phytochemistry, pharmacokinetics, pharmacology, and practical applications of Saussurea costus (Falc.) Lipsch: a review. J Ethnopharmacol 2026;367:121781 (PMID 42055098), 2026-08-10. pubmed.ncbi.nlm.nih.gov
- Sumaiya S, et al. Comparative efficacy of Aristolochia rotunda L. (Zarawand Mudaharaj) and Saussurea lappa C.B. Clarke (Qust) in primary dysmenorrhea - a single-blind randomized clinical study. Altern Ther Health Med 2024;30(8):6-14 (PMID 39110054), 2024-08. pubmed.ncbi.nlm.nih.gov
- Shum KC, et al. Authentication of Radix Aucklandiae and its substitutes by GC-MS and hierarchical clustering analysis. J Sep Sci 2007;30(18):3233-9 (PMID 18004716), 2007-12. pubmed.ncbi.nlm.nih.gov
- Chen F, et al. Authentication of Saussurea lappa, an endangered medicinal material, by ITS DNA and 5S rRNA sequencing. Planta Med 2008;74(8):889-92 (PMID 18537077), 2008-06. pubmed.ncbi.nlm.nih.gov
- Paulsen E. The sesquiterpene lactone mix: a review of past, present and future aspects. Contact Dermatitis 2023;89(6):434-441 (PMID 37820718), 2023-12. pubmed.ncbi.nlm.nih.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Dolomiaea costus (Falc.) Kasana & A.K.Pandey (accessed 2026-10-29; Kew cannot warrant the accuracy of the data), 2026-10-29. powo.science.kew.org
- UNEP-WCMC / CITES Secretariat. Species+: Saussurea costus (synonyms Saussurea lappa, Dolomiaea costus), CITES listing (retrieved 2026-10-29), 2026-10-29. speciesplus.net
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- Fallah A, et al. Placebo-controlled effect of topical Qust (Costus) oil on postmenopausal women's sexual desire disorder: a double-blind, randomized clinical trial. Eur J Transl Myol 2024;34(4):12660 (PMID 39286849; doi:10.4081/ejtm.2024.12660), 2024-09-16. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.